Results 131 to 140 of about 1,772,527 (156)

Myelodysplastic syndromes and utilisation of blood products in the era of hypomethylating agents

open access: yes
Myelodysplastic syndromes (MDS) are primary bone marrow disorders with clonal abnormalities in hematopoietic stem cells. It leads to ineffective hematopoiesis causing cytopenias as well as functional abnormalities.
Asma Ashraf (7451837)
core  

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome

open access: yesBlood Cancer Journal, 2022
Rami S. Komrokji   +8 more
doaj   +1 more source

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

open access: yesBlood Cancer Journal
Talha Badar   +16 more
doaj   +1 more source

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN

open access: yesBlood Neoplasia
Naveen Pemmaraju   +9 more
doaj   +1 more source

Epigenetics in Focus: Pathogenesis of Myelodysplastic Syndromes and the Role of Hypomethylating Agents

open access: yesCritical Reviews in Oncology/Hematology, 2013
Dysregulation of cellular epigenetic machinery is considered a major pathogenetic determinant in many malignancies, including myelodysplastic syndromes (MDS).
Clara Nervi   +2 more
exaly   +2 more sources

DNA-Hypomethylating Agents as Epigenetic Therapy Before and After Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Juvenile Myelomonocytic Leukemia

open access: yesSeminars in Cancer Biology, 2018
Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder, typically of older adults, which is characterized by ineffective hematopoiesis, peripheral blood cytopenias and risk of progression to acute myeloid leukemia.
Christian Flotho, Michael Lubbert
exaly   +2 more sources

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents [PDF]

open access: yesEBioMedicine, 2018
Somatic mutations contribute to the heterogeneous prognosis of chronic myelomonocytic leukemia (CMML). Hypomethylating agents (HMAs) are active in CMML, but analyses of small series failed to identify mutations predicting response or survival.
Mrinal M Patnaik   +2 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy